{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:29:18Z","timestamp":1748881758882,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To explore the efficacy of follitropin delta in ovarian stimulation of patients with the Rotterdam ESHRE\/ASRM 2003 phenotypes of polycystic ovarian syndrome (PCOS) using a retrospective case series with an electronic file search in a reproductive medicine clinic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Seventy-four patients with PCOS undergoing ovarian stimulation according to the individualized dosing algorithm of follitropin delta for in vitro fertilization\/intracytoplasmic sperm injection (IVF\/ICSI)\/oocyte freezing were included. Follitropin delta resulted in a high number of pre-ovulatory follicles at the end of stimulation as expected in patients with PCOS. There was a large number of oocytes retrieved with an acceptable percentage of metaphase II (MII) oocytes. There were no cases of moderate or severe OHSS across all phenotypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Follitropin delta, using the individualized dosing algorithm, appears to be a safe method of ovarian stimulation with a low risk of OHSS in PCOS patients without sacrificing successful stimulation outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-021-00773-5","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T20:35:32Z","timestamp":1613162132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Low risk of OHSS with follitropin delta use in women with different polycystic ovary syndrome phenotypes: a retrospective case series"],"prefix":"10.1186","volume":"14","author":[{"given":"Stephanie","family":"Yacoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Cadesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-462X","authenticated-orcid":false,"given":"Robert F.","family":"Casper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"773_CR1","volume":"4","author":"H Al-Inany","year":"2016","unstructured":"Al-Inany H, Youssef M, Ayeleke R, Brown J, Lam W, Broekmans F. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.","journal-title":"Cochrane Database Syst Rev"},{"key":"773_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.rbmo.2018.10.012","volume":"38","author":"E Bosch","year":"2019","unstructured":"Bosch E, Havelock J, Martin F, Rasmussen B, Klein B, Mannaerts B, et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind phase 3 safety trial. Reprod Biomed Online. 2019;38:195\u2013205.","journal-title":"Reprod Biomed Online"},{"key":"773_CR3","doi-asserted-by":"crossref","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI. Hum Reprod Open. 2020;(2):hoaa009.","DOI":"10.1093\/hropen\/hoaa009"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/humrep\/deu272","volume":"30","author":"R Briggs","year":"2014","unstructured":"Briggs R, Kovacs G, MacLachlan V, Motteram C, Baker H. Can you ever collect too many oocytes? Hum Reprod. 2014;30:81\u20137.","journal-title":"Hum Reprod"},{"key":"773_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1177\/1933719114522525","volume":"21","author":"N Clark","year":"2014","unstructured":"Clark N, Podolski A, Brooks E, Chizen D, Pierson R, Lehotay D, et al. Prevalence of polycystic ovary syndrome phenotypes using updated criteria for polycystic ovarian morphology. Reprod Sci. 2014;21:1034\u201343.","journal-title":"Reprod Sci"},{"key":"773_CR6","first-page":"370","volume":"2","author":"P Drakopoulos","year":"2016","unstructured":"Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al. Conventional ovarian stimulation and single embryo transfer for IVF\/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;2:370\u20136.","journal-title":"Hum Reprod"},{"key":"773_CR7","first-page":"19","volume":"81","author":"BCJM Fauser","year":"2004","unstructured":"Fauser BCJM, Tarlatzis B, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19\u201325.","journal-title":"Fertil Steril"},{"key":"773_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.rbmo.2018.12.032","volume":"38","author":"M Fern\u00e1ndez-S\u00e1nchez","year":"2019","unstructured":"Fern\u00e1ndez-S\u00e1nchez M, Visnova H, Yuzpe A, Klein B, Mannaerts B, Arce J. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online. 2019;38:528\u201337.","journal-title":"Reprod Biomed Online"},{"key":"773_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0042-100206","volume":"76","author":"D Fischer","year":"2016","unstructured":"Fischer D, Reisenb\u00fcchler C, R\u00f6sner S, Haussmann J, Wimberger P, Goeckenjan M. Avoiding OHSS: controlled ovarian low-dose stimulation in women with PCOS. Geburts Frauenheilkunde. 2016;76:718\u201326.","journal-title":"Geburts Frauenheilkunde"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/humrep\/den433","volume":"24","author":"A Goverde","year":"2008","unstructured":"Goverde A, van Koert A, Eijkemans M, Knauff E, Westerveld H, Fauser B, et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2008;24:710\u20137.","journal-title":"Hum Reprod"},{"key":"773_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.fertnstert.2010.03.028","volume":"94","author":"P Humaidan","year":"2010","unstructured":"Humaidan P, Quartarolo J, Papanikolaou E. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94:389\u2013400.","journal-title":"Fertil Steril"},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EC-17-0067","volume":"6","author":"W Koechling","year":"2017","unstructured":"Koechling W, Plaksin D, Croston G, Jeppesen J, Macklon K, Andersen C. Comparative pharmacology of a new recombinant FSH expressed by a human cell line. Endocr Connect. 2017;6:297\u2013305.","journal-title":"Endocr Connect"},{"key":"773_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/0974-1208.86080","volume":"4","author":"P Kumar","year":"2011","unstructured":"Kumar P, Sait FS, Shaema A, Kumar M. Ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2011;4:70\u20135.","journal-title":"J Hum Reprod Sci"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106:6\u201315.","journal-title":"Fertil Steril"},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson S, Fauser B, Garc\u00eda-Velasco J, Klein B, Arce J, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387\u2013396.e4.","journal-title":"Fertil Steril"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.fertnstert.2005.07.1292","volume":"85","author":"E Papanikolaou","year":"2006","unstructured":"Papanikolaou E, Pozzobon C, Kolibianakis E, Camus M, Tournaye H, Fatemi H, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112\u201320.","journal-title":"Fertil Steril"},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"E238","DOI":"10.1152\/ajpendo.90684.2008","volume":"296","author":"A Piouka","year":"2009","unstructured":"Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-M\u00fcllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol-Endocrinol Metab. 2009;296:E238\u201343.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjod.90094","volume":"13","author":"S Sel\u00e7uk","year":"2016","unstructured":"Sel\u00e7uk S, \u00d6zkaya E, Eser A, Kuyucu M, Kutlu H, Devrano\u011flu B, et al. Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. J Turkish Soc Obstet Gynecol. 2016;13:1\u20136.","journal-title":"J Turkish Soc Obstet Gynecol"},{"key":"773_CR19","doi-asserted-by":"publisher","first-page":"59.e1","DOI":"10.1016\/j.ajog.2014.02.026","volume":"211","author":"R Tal","year":"2014","unstructured":"Tal R, Seifer D, Khanimov M, Malter H, Grazi R, Leader B. Characterization of women with elevated antim\u00fcllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211:59.e1\u20138.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00773-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-021-00773-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00773-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T21:00:35Z","timestamp":1613163635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00773-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00773-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"type":"electronic","value":"1757-2215"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. Retrospective clinic quality review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Operating grant from Ferring Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}